Autologous Hematopoietic Stem Cell Transplant: How Long Does It Take in Korea? (2026 Guide)

Autologous hematopoietic stem cell transplant is a treatment in which a patient's own stem cells are collected in advance and infused back after high-dose chemotherapy. As of 2026, the total stay is typically planned at 6 to 8 weeks, including 3 to 6 weeks of hospitalization, and patients often return home about 2 to 3 weeks after discharge for autologous transplants.

Key Summary

• In autologous transplant, the patient's own hematopoietic stem cells are collected and frozen while the disease is under control, then infused back after high-dose chemotherapy. There is no rejection risk, but there is a possibility that cancer cells may be mixed in with the collected cells.
• Engraftment—when the new cells settle in and begin producing blood—usually takes 2 to 4 weeks, and patients stay in a sterile isolation room during this period due to high infection risk.
• As of 2026, the typical total stay is 6 to 8 weeks, including 3 to 6 weeks of hospitalization, and for autologous transplants patients often plan to return home about 2 to 3 weeks after discharge.
• Autologous transplant is the more common choice for multiple myeloma and relapsed lymphoma, while allogeneic transplant is more common for acute leukemia.
• The remote review (pre-arrival review) fee is KRW 1,000,000 (about US$730), which is deducted from the treatment cost once a treatment contract is signed (based on National Cancer Center Korea, NCCN patient guidelines, and Medical Korea).

What Is Autologous Transplant and Why Is It Done?

• Autologous transplant involves collecting and freezing the patient's own hematopoietic stem cells while the disease is under control, then infusing them back after high-dose chemotherapy has cleared out the bone marrow, allowing the marrow to resume producing blood.
• The transplant itself is not surgery—it is closer to a blood transfusion in which cells are infused through a vein. The difficult parts are the high-dose conditioning chemotherapy beforehand and the recovery period afterward.
• Because the patient's own cells are used, there is no risk of graft-versus-host disease (GVHD), in which a donor's immune cells attack the body. However, there remains a possibility that cancer cells could be mixed in with the collected cells.
• Candidates for autologous transplant include patients undergoing treatment for multiple myeloma and those with relapsed lymphoma or lymphoma that has not responded to standard treatment. Whether the procedure is performed also depends on age, overall condition, and heart, lung, liver, and kidney function.

What Is the Actual Sequence, and How Long Does Each Step Take?

1. Step 1: During the first 1 to 2 weeks after arrival, staging tests, heart/lung/liver/kidney function tests, and infection screening are performed, and a central venous catheter is placed for chemotherapy and transfusions.
2. Step 2: Conditioning chemotherapy is given for about 1 week to clear the diseased bone marrow.
3. Step 3: On the designated day, the patient's previously collected hematopoietic stem cells are infused intravenously. The infusion itself takes only a few dozen minutes.
4. Step 4: Patients spend 2 to 4 weeks in a sterile isolation room until engraftment is confirmed. During this period, fever, mouth sores, and low blood cell counts are common, and this is a period supported by transfusions and antibiotics.
5. Step 5: Once engraftment is confirmed and the patient's condition is stable, they are discharged—but do not return home immediately. Instead, they remain within walking distance of the hospital for frequent outpatient visits. For autologous transplant, the typical targets are 3 to 6 weeks of hospitalization and 6 to 8 weeks of total stay, with 2 to 3 weeks after discharge often serving as the benchmark for returning home.

What About Side Effects and Recovery?

• During the conditioning period, nausea, mouth sores, diarrhea, hair loss, and severe fatigue are common. During the period when blood cell counts drop, infection and bleeding are the greatest risks, so even a slight fever prompts immediate response.
• It takes several months for strength and immunity to return, and patients often need to restart vaccinations from scratch. After returning home, a handover document and a three-way video consultation are prepared together so that a local hematology department can take over care.

FAQ — Which Should Be Considered First, Autologous or Allogeneic Transplant?

For multiple myeloma and relapsed lymphoma, autologous transplant is the more common choice, while for acute leukemia, allogeneic transplant using donor cells is more common when the risk of relapse is judged to be high. Autologous transplant carries no rejection risk but has a possibility of cancer cells being mixed in, whereas allogeneic transplant has the benefit of donor immune cells attacking any remaining cancer cells, but requires management of graft-versus-host disease. The medical team determines which option is appropriate based on disease type, age, and organ function.

FAQ — Why Is the Stay Shorter for Autologous Transplant Than Allogeneic Transplant?

With allogeneic transplant, donor immune cells can cause graft-versus-host disease, so close monitoring for about 100 days after transplant is often the standard. Autologous transplant, however, uses the patient's own cells, so this risk does not apply, and patients may consider returning home about 2 to 3 weeks after engraftment is confirmed and they are discharged. That said, the final timing of return is determined by the medical team based on engraftment status and the degree of blood cell count recovery.

Sources and Notes

• This article was written based on notes on hematopoietic stem cell transplantation and blood cancers (based on National Cancer Center Korea, NCCN patient guidelines, and Medical Korea).
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult with a medical professional to determine an accurate diagnosis and treatment plan.